Biotech Values

[crudeoil24]

VIR > GlaxoSmithKline To Make $250M Equity Investment In Vir
8:05 am ET April 6, 2020 (Benzinga) VIR up 29% 37.62
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks


Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months


GSK to make equity investment of $250 million in Vir
LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.